Search Results
Your search for ,ShE matches 5598 pages
Showing 2951 - 3000Emily Whitehead, Early Recipient of CAR T-Cell Therapy for ALL, Celebrates 7 Years Cancer-Free
Among the success stories in the treatment of acute lymphoblastic leukemia (ALL) in children and young adults is the development of chimeric antigen receptor (CAR) T-cell therapy. The field of cellular immunotherapy was still in its infancy in 2012 when Emily Whitehead, then 7, became the first...
AYA Survivors Should Be Allowed to Participate in Adult Clinical Trials
When strangers ask me how many children I have, I’m not quite sure how to respond. Do I still have four children even though one has died? A year and a half after my son Brent’s death, at the age of 18, from complications of acute myeloid leukemia (AML), I’m still struggling with knowing the...
Lifestyle Modifications and Screening of Patients at High Risk Can Reduce Deaths From Pancreatic Cancer
After disclosing that he had been diagnosed with stage IV pancreatic cancer, Alex Trebek, longtime host of the popular television game show Jeopardy!, vowed that he would beat the disease despite the low associated survival rate. His statement has brought pancreatic cancer back into the public...
AACR Inaugurated New Leadership at 2019 Annual Meeting
The American Association for Cancer Research (AACR) inaugurated Elaine R. Mardis, PhD, as President for 2019–2020 during the 2019 AACR Annual Meeting. Dr. Mardis holds the Nationwide Foundation Endowed Chair in Genomic Medicine and is Co–Executive Director of the Institute for Genomic Medicine at...
Rookie
His steps generated a low rumble that propagated through the floor like a tsunami, flowed up through my desk, and ended as tiny waves visible through the clear plastic of my water bottle. His custom Lucchese ostrich boots made a distinctive clicking sound as they rhythmically struck the tile floor, ...
NCCN Recognizes Five Individuals for Achievements in Cancer Care
THE NATIONAL Comprehensive Cancer Network® (NCCN®) has announced the recipients of a series of awards honoring individuals whose contributions have fueled progress in improving and facilitating quality, effective, efficient, and accessible cancer care over the past year. They are Timothy J....
City of Hope Awarded $7.5 Million for Research in Cutaneous T-Cell Lymphoma
CITY OF HOPE recently received $7.5 million in grant awards to study the rare blood cancer cutaneous T-cell lymphoma. The National Cancer Institute (NCI) awarded two grants valued at $6.3 million over 5 years to City of Hope’s Steven Rosen, MD, and Christiane Querfeld, MD, PhD, so they can develop...
Debating the Role of Opioids in the Management of Chronic Cancer Pain
Despite the increasing public awareness of the danger of the overuse of prescription opioids, drug overdose deaths continue to rise in the United States. According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2017, nearly 400,000 people died of an overdose involving...
USC Norris Comprehensive Cancer Center Appoints Caryn Lerman, PhD, as Director
Caryn Lerman, PhD, has been appointed Director of the USC Norris Comprehensive Cancer Center, also serving as Professor of Psychiatry and the Behavioral Sciences. Prior to this appointment, Dr. Lerman was the John H. Glick Professor for Cancer Research and Vice Dean for Strategic Initiatives in...
Margaret Foti, PhD, MD (hc), Receives 2019 Women of Inspiration and Influence Award
Women Business Leaders (WBL), of the U.S. Health Care Industry Foundation, recently recognized American Association for Cancer Research (AACR) Chief Executive Officer Margaret Foti, PhD, MD (hc), with the 2019 Women of Inspiration and Influence award. Dr. Foti is among 11 senior executive women...
Francoise Mornex, MD, PhD, Named First Female Recipient of Heine H. Hansen Award
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) recently awarded the 2019 Heine H. Hansen Award to Francoise Mornex, MD, PhD. The award was presented at the 2019 European Lung Cancer Congress. Dr. Mornex is Professor of...
Ghanaian Oncologist Yehoda M. Martei, MD, Seeks Ways to Improve Outcomes in the Developing World
Breast cancer remains the most commonly diagnosed cancer among women globally. Due to a lack of early interventions, most women in low- and middle-income countries have advanced disease at the time of diagnosis, conferring a grim prognosis. Yehoda M. Martei, MD, of the Department of Medicine,...
Measuring the Burden of Global Cancer as a Tool for Policymakers
The Global Burden of Disease Study was initiated in 1990, commissioned by the World Bank. At that time, the study was conducted mainly by researchers at Harvard and the World Health Organization (WHO). Since then the study has gone through many iterations to its present structure, which is a...
Margo Shoup, MD, FACS, Appointed Network Chair of Nuvance Health Cancer Service Line
Margo Shoup, MD, FACS, has been appointed Network Chair of the Cancer Service Line for the new health system formed by Health Quest and Western Connecticut Health Network (WCHN), to be called Nuvance Health. Dr. Shoup will provide strategic and clinical leadership for all aspects of Nuvance...
AACR Honors Elaine Fuchs, PhD, With 2019 AACR G.H.A. Clowes Memorial Award
The American Association for Cancer Research (AACR) has awarded the 59th AACR G.H.A. Clowes Memorial Award to Elaine Fuchs, PhD. The award was presented during the AACR Annual Meeting 2019. Dr. Fuchs delivered her award lecture, “Stem Cells in Wound Repair, Inflammation, and Cancer,” at the Georgia ...
Teen Cancer America Announces New Advisory Council
Teen Cancer America (TCA), the national nonprofit organization founded by rock artists Roger Daltrey and Pete Townshend of The Who, recently announced appointments to its newly formed Advisory Council. Based in Los Angeles, TCA develops specialized facilities as well as treatment- and age-specific...
How Cancer Affects Adolescents and Young Adults
The statistics are alarming: according to the National Cancer Institute (NCI), about 70,000 adolescents and young adults (AYAs) are diagnosed with cancer each year1—a recent report by the University of California put that figure at 87,000.2 Although overall cancer survival rates continue to improve ...
Anjali Mishra, PhD, and Nitin Chakravarti, PhD, Join Sidney Kimmel Cancer Center at Jefferson Health
The Sidney Kimmel Cancer Center–Jefferson Health (SKCC) recently welcomed Anjali Mishra, PhD, and Nitin Chakravarti, PhD, to its team of researchers focused on hematologic cancers. Both Drs. Mishra and Chakravarti are Assistant Professors in the Department of Medical Oncology. Dr. Mishra is a...
Lisa Kachnic, MD, Joins Columbia University as Chair of Radiation Oncology
Lisa Kachnic, MD, has been named Chair of the Department of Radiation Oncology at the Columbia University Vagelos College of Physicians and Surgeons and Chief of the Radiation Oncology Service at NewYork-Presbyterian/Columbia University Irving Medical Center. She will also serve as Associate...
NCCN Roundtable Tackles Issues With Innovative Immunotherapies
Immunotherapies are radically changing outcomes, but while helping patients, they are creating complexities surrounding their cost. At the 2019 Annual Conference of the National Comprehensive Cancer Network® (NCCN®), a roundtable of experts, including clinicians and payers, discussed how chimeric...
Gareth Morgan, MD, PhD, and Faith Davies, MD, Join New Center for Blood Cancers at NYU Langone Health
Hematology experts Gareth Morgan, MD, PhD, and Faith Davies, MD, have joined the Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center and will lead its multiple myeloma program. About Dr. Morgan Dr. Morgan, the Center’s Director of Multiple Myeloma Research, previously served...
2019 NCCN Posters Explore Next-Generation Sequencing, Cancer Burden vs Funding, Cardiac Monitoring, and Scalp Cooling
Posters presented at the National Comprehensive Cancer Network® (NCCN®) Annual Conference continue to grow in number and in quality. The ASCO Post presents a few that we found interesting at the recent 2019 meeting. Next-Generation Sequencing Not Always Helpful in Practice The value of...
Expert Point of View: Marcie L. Riches, MD, MS
Marcie L. Riches, MD, MS, Director of Clinical Research and Data Quality and Bone Marrow Transplant Clinic Medical Director, and Clinical Associate Chief of Hematology/Oncology at the University of North Carolina at Chapel Hill, commented on the study of tabelecleucel for The ASCO Post. At the...
T-Cell Therapy for EBV-Associated Posttransplant Lymphoproliferative Disorder With CNS Involvement
An “off-the-shelf” allogeneic T-cell product, tabelecleucel, may effectively treat patients who develop Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder with central nervous system (CNS) involvement, researchers from Memorial Sloan Kettering Cancer Center reported at...
ASCO Guideline Recommends Shorter-Course Adjuvant Chemotherapy for Some Patients With Stage III Colon Cancer
In a clinical practice guideline released April 15, an ASCO Expert Panel outlined the latest recommendations for the duration of adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin for patients with completely resected stage III colon cancer.1 New recommendations were based on the results ...
Locoregional Recurrence After Mastectomy for DCIS More Common Among Younger Women, Study Finds
Young age appears to be a risk factor for locoregional recurrence after mastectomy for ductal carcinoma in situ (DCIS) with or without microinvasion, according to data presented at the 2019 Society of Surgical Oncology Annual Cancer Symposium.1 The retrospective analysis of more than 3,000 cases...
Susan G. Komen Welcomes Five Leaders to New Research Advisory Roles
Susan G. Komen recently announced new organizational advisory roles for five breast cancer oncologists. The new appointees will join the group of breast cancer researchers, clinicians, and advocates who help guide the organization’s work, particularly through the organization’s $988 million...
Evidence Mounts for Tumor Mutational Burden as Biomarker of Immune Checkpoint Inhibitor Benefit in NSCLC
The search for biomarkers to identify patients who are likely to respond to immunotherapy continues. According to biomarker tissue and blood analysis of patients enrolled in the phase III MYSTIC trial, high tumor mutational burden in both tissue and blood identified patients with non–small cell...
Expert Point of View: Efrat Dotan, MD, and Colin D. Weekes, MD, PhD
Efrat Dotan, MD, Associate Professor, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, commented on this study. “This abstract presents the interim analysis of a phase II study evaluating the use of maintenance therapy with the poly (ADP-ribose) polymerase PARP inhibitor...
Study Shows Rucaparib Active as Maintenance Therapy in Pancreatic Cancer
The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib holds promise as maintenance therapy for advanced, platinum-sensitive, BRCA- or PALB2-mutated pancreatic cancer, according to an interim analysis of an ongoing phase II clinical trial presented at the 2019 Annual Meeting of the American...
NCCN Clinical Practice Guidelines in Oncology: 2019 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®), covering eight tumor types. NCCN Guidelines are now published for more than 70 tumor types and topics. Some of the key updates for 2019 were presented...
Study Finds Less Chemotherapy Noninferior to More in Frail and Elderly Patients With Advanced Gastroesophageal Cancer
A large randomized trial has found that frail and elderly patients with advanced gastroesophageal cancer may be safely and successfully treated with dose-reduced chemotherapy. In the GO2 phase III trial, low doses of oxaliplatin/capecitabine performed similarly to intermediate and high doses of the ...
Expert Point of View: Tracy Rose, MD, MPH
THE FORMAL DISCUSSANT of the KEYNOTE-427 trial, Tracy Rose, MD, MPH, of the University of North Carolina, Chapel Hill, told listeners: “I think pembrolizumab should now be considered an option for non–clear cell kidney cancer. Response rates, however, remain inferior to those seen in clear cell...
Marking a Year of Learning From ASCO Members
This past year, I have traveled thousands of miles across the United States meeting with ASCO members and their patients, focusing on members who care for patients in particularly challenging settings. While I am not surprised by the extraordinary work our members are doing in every region of the...
Expert Point of View: Irene Ghobrial, MD, and Monica M. Bertagnolli, MD, FACS, FASCO
Irene Ghobrial, MD, of Dana-Farber Cancer Institute and Harvard Medical School, Boston, who has conducted seminal trials in smoldering myeloma, commented on the phase III E3A06 study. Asked by The ASCO Post whether E3A06 settles the issue of treating smoldering disease, Dr. Ghobrial responded,...
Does Quitting Smoking Affect Risk of Bladder Cancer in Postmenopausal Women?
A large study of postmenopausal women indicated that quitting cigarette smoking was associated with significantly reduced risk of bladder cancer. The most significant reduction in risk occurred in the first 10 years after quitting, with a modest but continued decline in later years. These results...
Study Finds Immune Enrichment Improves Outcomes in Pancreatic Cancer With Activated but Not Normal Stroma
ALTHOUGH IMMUNOTHERAPIES have had limited success in pancreatic cancer to date, findings from a molecular analysis of the tumor microenvironment suggest that certain subtypes may be more responsive to treatment. According to data presented at the 2019 Society of Surgical Oncology Annual Cancer...
AACR Study Presentations Include New Data in Breast and Prostate Cancers, Sarcoma, and High-Risk Individuals
THE 2019 American Association for Cancer Research (AACR) Annual Meeting was held March 29 to April 3 in Atlanta. In addition to our regular coverage of news stories from the meeting, here are some brief highlights of additional noteworthy studies. Stage IV HER2-Positive Breast Cancer: Surgery or No ...
Expert Point of View: Namrata Vijayvergia, MD
NAMRATA VIJAYVERGIA, MD, of Fox Chase Cancer Center, Philadelphia, commented on this study. “This is an important study because it is done in a rare tumor type; not a lot of clinical trials are conducted in this disease. Recently, three other studies of single-agent therapy with checkpoint...
Osimertinib Plus Savolitinib in Advanced NSCLC Driven by MET Resistance
THE ADDITION of the MET inhibitor savolitinib to the EGFR inhibitor osimertinib led to activity in patients with MET-amplified, EGFR-mutated non–small lung cancer (NSCLC) with acquired resistance to previous therapies, according to interim results from two expansion cohorts of a phase Ib clinical...
Harnessing the Power of Twitter for Clinical Trial Enrollment and Success
CLINICAL TRIALS are vital for advancing cancer care for our patients. Each trial represents an unanswered problem for which researchers are committed to solving. Designing, funding, recruiting, and completing a trial are tremendous undertakings for each researcher, physician, patient, and...
ASBrS 2019: Opioid Management Program Reduces Post–Breast Surgery Narcotic Use
A breast surgery opioid prescription management program that analyzed current physician patterns and provided education and guidelines successfully reduced the volume of narcotics given postoperatively to patients at a large institution. These results were presented by Fan et al at the Annual...
ASBrS 2019: Retrospective Study of Nipple-Sparing Mastectomy Outcomes Over Time
Nipple-sparing mastectomy complication and implant failure rates have decreased significantly since introduction of the procedure, while the patient population undergoing nipple-sparing mastectomy increasingly includes more advanced cancers and women traditionally considered at risk for...
ASBrS 2019: Bioimpedance Spectroscopy for Surveillance of Breast Cancer–Related Lymphedema
Surveillance of women at risk for breast cancer–related lymphedema using bioimpedance spectroscopy was more effective in preventing lymphedema progression than traditional arm circumference measurement when each was combined with immediate compression therapy. These were the results of an...
ASBrS 2019: Factors Associated With Nonoperative Management of Select Patients With HER2-Positive Breast Cancer
Tumor hormonal status, possible ductal carcinoma in situ (DCIS) on initial biopsy, and imaging results following neoadjuvant chemotherapy may help physicians predict whether surgery might be safely eliminated for HER2-positive breast cancer that is traditionally treated aggressively....
ESTRO 38: What Type of Radiotherapy May Best Preserve Cognitive Function in Pediatric Patients With Brain Tumors?
A comparison of three types of radiotherapy for pediatric brain tumors suggests that a type of proton therapy called pencil-beam scanning (PBS) offers the best hope of preserving cognitive functions. The study, presented by Toussaint et al at ESTRO 38, the annual congress of the European Society...
ESTRO 38: High–Dose Rate Brachytherapy in Localized Prostate Cancer
A single high dose of radiation that can be delivered directly to a treatment site within a few minutes is a safe and effective technique for treating men with localized, low-risk prostate cancer, according to a study presented by Tharmalingam et al at ESTRO 38, the annual congress of the ...
ESMO Breast Cancer 2019: Does Continuous Chemotherapy Benefit Patients With Advanced Breast Cancer?
Continuous chemotherapy showed greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented by Erdkamp et al and Claessens et al at the European...
ESMO Breast Cancer 2019: PERNETTA Trial Examines Treatment De-escalation in Women With HER2-Positive Breast Cancer
De-escalation approaches in the treatment of women with HER2-positive breast cancer need to be personalized, according to a European Society for Medical Oncology (ESMO) spokesperson Carmen Criscitiello, MD, PhD, of the European Institute of Oncology in Milan, Italy. Dr. Criscitello commented on the ...
Cigall Kadoch, PhD, Chosen for 2019 Martin and Rose Wachtel Cancer Research Prize
The American Association for the Advancement of Science and Science Translational Medicine announced that Cigall Kadoch, PhD, has been chosen for the 2019 Martin and Rose Wachtel Cancer Research Prize. Dr. Kadoch is Assistant Professor of Pediatric Oncology at Dana-Farber Cancer Institute;...
